Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients

Abstract

BackgroundSurvivin is an inhibitor of apoptosis and a regulator of mitotic progression. TP53 protein is a negative transcriptional regulator of survivin. The aim of our study was to evaluate the clinical significance of survivin expression in advanced stages ovarian cancer with respect to the TP53 status.MethodsSurvivin and TP53 expression was evaluated immunohistochemically in 435 archival samples of ovarian carcinomas (244 patients were treated with platinum/cyclophosphamide-PC/PAC; 191-with taxane-platinum (TP) agents). Univariate and multivariate statistical analyses were performed in patients groups divided according to the administered chemotherapeutic regimen, and in subgroups with and without TP53 accumulation (TP53+ and TP53-, respectively).ResultsNuclear and cytoplasmic survivin expression was observed in 92% and 74% of the carcinomas, respectively. In patients treated with TP, high nuclear survivin expression decreased the risk of disease recurrence and death, and increased the probability of high platinum sensitivity (p < 0.01), but only in the TP53(+) group, and not in the TP53(-) group.ConclusionsIt appears that TP53 status determines the clinical importance of nuclear survivin expression in taxane-platinum treated ovarian cancer patients.

Survivin Expression as a Prognostic Factor in Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer Treated With Neoadjuvant Chemotherapy

“…No independent predictive and prognostic significance of survivin was observed in the group without p53 protein expression. 15 In our study, which assessed selected proteins of apoptosis, we found that high expression of survivin was a favorable prognostic factor in patients with AOC treated with NAC. As in the study by the Polish Ovarian Cancer Group, the effect was more significant in the group of patients with positive expression of p53.…”

The expression of HER-2/neu (c-erbB2), survivin and cycline D1 in serous ovarian neoplasms: their correlation with clinicopathological variables

“…They also observed that TP53 status determines the clinical importance of nuclear survivin expression in taxane-platinum treated ovarian cancer patients (Felisiak-Golabek et al 2011).…”

Multifunctional Polymeric Micelles Co-loaded with Anti–Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer

“…In the last years, the retrospective analysis of patient specimens and xenografts tumor data are pointing out that there is a clear connection between the existence of high levels of survivin protein and the resistance to therapy and poor prognosis in multiple tumor types (19–22). In the particular case of ovarian cancer, the prognostic role of survivin is not clear due to some conflicting results (23–26). However, the potential of survivin as a target for apoptosis-based therapy is well-established (27).…”